Impact of Restricted Medication Access on Care of Multiple Myeloma Patients

Overview

About this study

The purpose of this study is to evaluate differences in time to fill lenalidomide, pomalidomide and thalidomide (iMiDs) prescribed by a health-system provider (HSP) when the health-system specialty pharmacy is either 1) in both the limited distribution (LDD) network and payor network, 2) in the LDD network but payor lock out, or 3) not in the LDD network. To accomplish this aim, we will perform a mixed methods study using quantitative data to evaluate time to medication access and qualitative data using surveys to assess patient and provider experiences.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Eighteen (18) years or older.
  •  Active diagnosis of multiple myeloma.
  •  Newly started on lenalidomide, pomalidomide or thalidomide by a Cedars-Sinai provider:
    • “Newly started” is defined as patients without a previous prescription written for the respective iMiD on the EMR documentation system in the last 12 months.

Exclusion Criteria:

  • Prescriptions dispensed at a third party specialty pharmacy that is contracted with the participating medical center to dispense thalidomide, lenalidomide or pomalidomide.
  • Prescriptions initiated by a non-Mayo Clinic provider or if the original prescription was not found in the electronic health record.
  • Patients who were initiated on therapy during inpatient stay.
  • Patients who were initiated on therapy as part of a clinical trial.
  • Patients with records flagged “break the glass” or “research opt out.”

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/25/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Tyler Sandahl, Pharm.D., R.Ph., BCOP

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available